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School of Chemistry, University of Bristol, Cantock’s Close, Bristol BS8 1TS, UK  
j.clayden@bristol.ac.uk 
N-Acyl imidazolidinones, which are key intermediates in the stereoselective synthesis of amino acids by ‘self-regeneration 
of stereochemistry’ methods, are classically made by only moderately diastereoselective methods. We now report that cy-
clisation of pivaldimino-amides with phosgene in the presence of pyridine may be made fully diastereoselective for the 
trans-N-chloroformylimidazolidinones, and we detail the conformational features of the products. We show that despite 
the presence of the electrophilic carbamoyl chloride function, the products show remarkable stability, and may be deproto-
nated to form enolates with useful reactivity for the synthesis of amino acid derivatives. 
Introduction 
Several strategies for the synthesis of quaternary (a,a-disubstituted) amino acids entail the alkylation of the a-carbon of a 
readily available (and therefore usually L) amino acid.1–5 ‘Memory’ of the configuration at the a-centre that is lost during the 
formation of the intermediate enolate may be ensured in a number of ways,6–9 but the most practical and widely used 
method, originally developed by Seebach et al.,10 employs an imidazolidinone derivative containing a second stereogenic 
centre that directs a subsequent alkylation step (Scheme 1). Termed ‘self-regeneration of stereochemistry’, this method re-
quires a diastereoisomerically pure imidazolidinone intermediate of either cis or trans relative stereochemistry if the enan-
tiopurity of the product amino acid is to be maximised. Methods for the synthesis of both cis and trans imidazolidinones 
are reported, but neither are fully diastereoselective:11 classical applications of Seebach’s method require crystallisation of 
the imidazolidinone to remove the unwanted diastereoisomer.12 Which diastereoisomer of the intermediate is used deter-
mines the overall outcome of the reaction: the cis diastereoisomer retains the configuration of the original stereocentre 
while the trans diastereoisomer inverts it. Imidazolidinones have also found widespread use as organocatalysts for a wide 
range of reactions.13,14 
 
Scheme 1: Imidazolidinones as intermediates in the synthesis of quaternary amino acid derivatives 
  
	
Diastereoselectivity may be achieved because the trans imidazolidinone is formed under kinetic conditions, while the cis 
imidazolidinone is thermodynamically more stable.11,12 We now report in full our investigation of the cyclisation of an imine 
precursor with a phosgene source, which demonstrates that careful choice of solvent and conditions allows the fully dia-
stereoselective synthesis of a trans imidazolidinone. The trans product carries an N-chloroformyl substituent (Scheme 1, X = 
Cl) that may be readily converted to other functional groups, but also shows remarkable stability to basic conditions. We 
also report in full our investigation of the alkylation of the nucleophilic enolate derivatives of these simultaneously electro-
philic species. 
We have recently described several reactions in which the N-chloroformyl derivative of an imidazolidinone plays a pivot-
al role,15–18 and this work showed that the two diastereoisomers of these carbamoyl chlorides displayed very different reac-
tivity. In one particular family of Bischler-Napieralski-like cyclisations,16 only the trans isomer was of use. We thus set out 
to discover conditions for the general, stereoselective synthesis of N-chloroformylimidazolidinones as their trans isomers.  
 
Results and Discussion 
Initial work was carried out using the L-phenylalanine pivaldimine derivative 1a as our starting material. Diastereoselec-
tivity in the formation of the N-chloroformylimidazolidinone 2a from 1a and a phosgene source was explored using the 
conditions shown in Table 1. 
Treating 1a with phosgene (2.5 equiv.) in dry toluene provided the product 2a with excellent diastereoselectivity (Table 1, 
entry 1), but in only 40% yield after 18 h at 60 °C. Higher temperature (entry 2) only served to reduce yield and selectivity. 
Diastereoselectivity was maintained and the yield improved slightly in dry dichloromethane at rt (entry 3), while in THF the 
yield increased significantly, but at the expense of diastereoselectivity (entry 4). Acetonitrile and dioxane provided no im-
provement in yield or diastereoselectivity (entries 5, 6), and the alternative solid chloroformylating agent triphosgene gave 
almost no product (entries 7, 8). 	
Table 1: Trans-selective synthesis of N-chloroformylimidazolidinone 2a 
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1 toluene - 60 40 95:5 
2 toluene - 100 20 57:43 
3 CH2Cl2 - rt 48 96:4 
4 THF - rt 70 91:9 
5 MeCN - rt 35 80:20 
6 dioxane - rt 37 94:6 
7 CH2Cl2 -b rt trace 81:19 
8 CH2Cl2 -b 40 trace  54:46 
9 CH2Cl2 Et3N rt 0 - 
10 CH2Cl2 2,6-lutidine rt trace 37:63 
11 CH2Cl2 DMAP rt 32 85:15 
12 CH2Cl2 NaHCO3 rt 49 96:4 
13 CH2Cl2 K2CO3 rt 26 93:7 
14 THF py rt nd 70:30 
15 THF pyc rt 78 99:1 
16 THFd pyc rte 86 99:1 
aRatio of trans:cis in 1H NMR spectrum of crude reaction mixture. bUsing triphosgene ([Cl3CO]2CO, 0.5 equiv.) in place of phos-
gene. cSlow addition of COCl2; pyridine added after 2 h. dReaction carried out at 0.5 M. eFor 2.5 h. 
During reactions with phosgene (entries 1-6) in toluene, dioxane, THF or MeCN, a white precipitate started to form after 
10 minutes; in dichloromethane, similar precipitation occurred after 15 min, but the precipitate redissolved after a further 15 
min. The precipitate formed during the reaction shown in entry 3 was isolated by filtration and characterised as the pure 
trans imidazolidinone hydrochloride salt 3a, using NOE studies to establish relative configuration. 
Conditions were explored with the aim of retaining the trans selectivity of the cyclisation but avoiding the reduced yield 
that inevitably arises from precipitation of the hydrochloride salt. Triethylamine, lutidine, and DMAP (entries 9-11) re-
turned very poor yields of product, as did inorganic bases (12-13), albeit with improved diastereoselectivity. 
An alternative approach was tried, using THF to encourage precipitation of the hydrochloride salt, but neutralising with 
pyridine. A significant dependence on the timing of the addition was noted: when the pyridine was added at the start of the 
reaction (entry 14), selectivity was poor, but when the pyridine was added after 2 h (to allow precipitation of the diastereoi-
somerically pure hydrochloride salt), selectivity was excellent. Optimal conditions were found when the phosgene was add-
ed slowly (entry 15), and the yield was maximised to 86% of essentially pure (99:1) trans diastereoisomer by conducting the 
reaction at 0.5 M (entry 16). These optimal conditions proved general for a wide range of amino acid substrates, with only 
1.5 equiv. phosgene required for good yields on larger (>10 g) scales. A series of pivaldimine derivatives of the amino acid N-
methyl amides 1 gave the imidazolidinones 2a-2r from aromatic, heteroaromatic and aliphatic amino acids (Scheme 2). Dia-
stereoselectivity was in every case excellent, and the trans relative configuration of several of the products was confirmed by 
X-ray crystallography: Figure 1a-d illustrates the X-ray crystal structures of 2a, 2p and 2c. 
  
	
Scheme 2. Diastereoselective cyclisation of amino acid pivaldimines 1 to trans-N-chloroformylimidazolidinones 2. 
 
aRelative configuration confirmed by X-ray crystal structure: CCDC deposition numbers 2a 1899271; 2c 1871268; 2d 1899274; 2e 
1899273; 2m 1899272; 2n 1899277; 2p 1899276. bon 25 g scale; con 5 g scale. 
 We had previously noted that the trans diastereoisomers of the carbamoyl chlorides 2 were significantly less reac-
tive than their cis epimers,15 presumably because of steric encumbrance to attack on either face of the chloroformyl group. 
This steric hindrance also led to characteristic features in the 1H NMR spectra of 2 (and of their derivatives 3 described be-
low). Typically, two complete sets of signals were observed, corresponding to the two rotamers about the hindered, amide-
like N–CO bond. In the case of 2c, these two rotamers were identifiable in the X-ray crystal structure (Figure 1c and 1d). The 
signals corresponding to the rotamers of 2p coalesced at temperatures above 25 °C, and variable temperature NMR of 2p in 
d8-toluene (Figure 1e) allowed us to determine a barrier to conversion of the major to the minor rotamer of 63.4 kJ mol–1 at 
300 K by modelling the exchange-broadened line shapes (Figure 1g). The more hindered carbamoyl chloride derivative of 
isovaline 3d (formed by the method described below) also showed two rotamers in its NMR spectra (Figure 1f) which coa-
lesced at a higher temperature. Line shape modelling (Figure 1h) gave a correspondingly higher barrier to conversion of the 
major to the minor rotamer of 71.7 kJ mol–1 at 300 K. 
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(a)					(b)					(c)				(d)						
(e)	 	 	 	 	 	 (g)	
		
 
(f)      (h) 
 	
Figure 1: Stereochemistry and structure of N-chloroformylimidazolidinones. X-ray crystal structures of (a) 2a; (b) 
2p; (c) 2c (major conformer); (d) 2c (minor conformer); Portion of the 1H NMR spectrum of (e) 2p in d8-toluene between 
0 and 35 °C (showing coalescence of the two N–CO rotamers populated in a 60:40 ratio); (f) of 3d in d8-toluene between 
25 and 96 °C (showing coalescence of the two N–CO rotamers populated in a 55:45 ratio); Modelled line shapes for ex-
change rates indicated of (g) 2p; (h) 3d. 
 The remarkable stability of the carbamoyl chlorides 2 permitted them to be very readily isolated and purified by 
chromatography on silica, and suggested that despite their electrophilic reactivity it might nonetheless be possible to 
deprotonate them to form an enolate.18 In initial investigations, 2a was treated with base at room temperature and 
quenched with allyl bromide, but only decomposition was noted with LDA, KHMDS or LiHMDS (Table 2, entries 1-3). 
With LDA (2 equiv.) at lower temperature –100 °C with 2a, promisingly the alkylated product 3a was formed only in 20% 
yield (entry 4). Changing the base to KHMDS at –78 °C gave 3a successfully in excellent yield (entries 5, 6). Improved yield 
was ensured by minimising KHMDS equivalences (1.2 equiv.) at -78 °C. Using these conditions, the enolates from several 
imidazolidinones 2 were alkylated diastereoselectively to form stable, isolable N-chloroformylimidazolidinone derivatives 
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of quaternary amino acids 3, as shown in Scheme 3. 3b was formed from the cis diastereoisomer of the imidazolidinone 
cis-2b.15 The relative stereochemistry of the products 3d and 3g were confirmed by NOE (See Supporting Information). 	
Table 2: Diastereoselective alkylation of trans-N-chloroformylimidazolidinones 2a 
Entry Base Equiv. T / °C Yield (%), dr 
1 LDA 2 eq. rt 0a 
2 KHMDS 1 eq. rt 0a 
3 LiHMDS 1 eq. rt 0a 
4 LDA 2 eq. -100 20, >95:5 
5 KHMDS 2 eq. -78 80, >95:5 
6 KHMDS 1.2 eq. -78 86, >95:5 
aDecomposition. 		
Scheme 3. Diastereoselective alkylations of trans-N-chloroformylimidazolidinones 2. 
 
aFrom the cis diastereoisomer of 2b. bRelative configuration confirmed by NOE. 
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The diastereoselective alkylation of the carbamoyl chlorides 2 provides an alternative to the use of N-acylated imidazol-
idinones in classical ‘self-regeneration of stereocentres’ chemistry, but with a more readily removed nitrogen substituent. 
The alkylated products 3 were readily hydrolysed to the quaternary amino acids or their N-methyl amides, as shown for 
3b and 3d in Scheme 4. 4 is the fungal metabolite L-isovaline, and its absolute configuration was confirmed by compari-
son of its optical rotation with the literature value.19  
Imidazolidinones are also well established as organocatalysts.13,14 The diastereoisomerically pure trans N-
chloroformylimidazolidinone 2 could be converted to cis Cbz derivative 6, an organocatalyst precursor.20,21 The use of the 
benzyloxide anion entails epimerisation of the amino acid centre, giving from L-phenylalanine the diastereoisomerically 
pure cis imidazolidinone derivative of D-phenylalanine 6. The relative stereochemistry of 6 was determined by X-ray crys-
tal structure (Scheme 4). 
Scheme 4: Transformations of the N-chloroformyl group. 
 
aCCDC deposition number for 6: 1899275.  
In summary, we show that cyclisation of the pivaldimine derivatives of natural amino amides using phosgene in THF in 
the presence of pyridine allows fully diastereoselective formation of carbamoyl chloride derivatives of trans imidazoli-
dinones. These have sufficient reactivity to be converted to carbamate protected derivatives, but also display remarkable 
stability, allowing the carbamoyl chlorides themselves to be used as intermediates in amino acid synthesis. 
 
Experimental Section 
General Information 
Where specified, reactions requiring anhydrous conditions were performed under dry nitrogen or argon atmospheres in 
glassware that was dried using either a combination of vacuum and heat gun, oven, or flame drying. Reaction mixtures 
were stirred magnetically. Air- and moisture-sensitive liquids and solutions were transferred via syringe or cannula into 
the reaction vessels through rubber septa. All reagents were purchased at highest commercial quality and used as received 
(unless specified otherwise). Solvents were purchased at the highest commercial quality and used as received (unless 
specified otherwise). Anhydrous CH2Cl2, Et2O, THF and MeCN were collected under argon from an Anhydrous Engineer-
ing alumina-column drying system. Anhydrous pyridine stored over 3 Å molecular sieves was purchased from Acros. All 
reaction temperatures described below −10 °C were achieved using acetone/dry ice cooling baths. 
E
N
N
O
Met-Bu
Cl
O R
3
HCl (6 M),
TFA (4:1)
DOWEX
50WX8
H2N CO2H
4, 87%
H2N CONHMe
5, 80%
Cl
BnOH (1.1 equiv.)
NaH (1.1 equiv.)
THF, 0-20 °C N N
O
Met-Bu
BnO
O
6, 63% 
>99:1 dr
N
N
O
Met-Bu
Cl
O
2a
X-ray crystal structure of 6a
  
8 
Analytical Information 
Rf: TLC was performed on aluminium backed silica plates (0.2 mm, 60 F254) which were developed using standard visualis-
ing agents: UV fluorescence (254 & 366 nm), phosphomolybdic acid, vanillin, potassium permanganate and Seebach 
stains. 
Chromatography: Flash chromatography was performed on an automated Biotage Isolera Spektra Four using gradient 
elution on pre-packed silica gel Biotage SNAP Ultra columns. 
mp: Melting points (mp), expressed in °C, were measured on a Kofler hotstage melting point apparatus and are uncor-
rected. 
IR: IR spectra were recorded from neat compounds applied as thin films on a Perkin Elmer (Spectrum One) FT-IR spec-
trometer (ATR sampling accessory). Only absorbances of interest (νmax expressed in cm−1) are reported. In situ IR meas-
urements were performed using a Mettler Toledo ReactIR 15 instrument equipped with a 6.3 mm AgX DiComp probe and 
iC IR software. 
NMR: Spectra were recorded on Varian VNMR (400 MHz or 500 MHz) instruments, and Bruker Ultrashield (400 MHz or 
500 MHz) spectrometers. Chemical shifts (δ) are quoted in parts per million (ppm) downfield of trimethylsilane. Spectra 
were calibrated using the residual solvent peaks for CDCl3 (δH: 7.26 ppm; δC: 77.16 ppm) or CD3OD (δH: 3.31 ppm; δC: 49.00 
ppm) as appropriate. Coupling constants (J) are rounded to the nearest 0.1 Hz. Splitting patterns are abbreviated to: sin-
glet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad (br.) or some combination thereof. 2D NMR experiments 
COSY, HSQC and HMBC were used in assigning NMR spectra where necessary. 
MS: Low resolution mass spectra were recorded by the technical staff at the University of Bristol on a Bruker Daltronics 
MicrOTOF 2 mass spectrometer (ESI), with only molecular ions of interest ([M]+, [M + H]+, [M + Na]+) reported. 
HRMS: High resolution mass spectra were recorded by the technical staff at the University of Bristol on a Bruker Daltron-
ics MicrOTOF 2 mass spectrometer (ESI). 
Optical Rotations: ([α]$%) Optical rotations were measured on a Bellingham and Stanley Ltd. ADP220 polarimeter using 
a cell with a pathlength of 0.25 dm with the solvent quoted and concentration (c) given in g/100 mL. 
X-Ray Sample Preparation: Crystals suitable for X-ray were grown by dissolving the sample in a dense solvent (CH2Cl2) 
in which it is reasonably soluble which is then placed inside a second chamber containing a less dense solvent (Hexane or 
n-Pentane). The solvents slowly mixed together, altering the polarity of the solution in which the sample is dissolved, 
leading to crystallisation. 
Precursors: All esters, amides, and imines (precursors to the N-chloroformylimidazolidinones) were synthesised on 10-30 
gram scale according to our previously reported literature protocols.15-17 
General Procedure 1: Synthesis of trans N-chloroformylimidazolidinones 
The synthesis of N-chloroformylimidazolidinones on 10-30 gram scale according to our optimised method was previously 
reported.16-17 Phosgene solution (15% wt. in toluene, 1.5 equiv.) (handle carefully!) was added dropwise to a solution of the 
imine (1 equiv.) in dry THF (0.5 M) at room temperature under N2 over approximately 30 min. A precipitate is typically 
observed 10-15 min after addition. After 2 h, pyridine (2 equiv.) was added dropwise. After stirring for a further 30-60 min, 
aqueous HCl (10 ml, 1.0 M) was added. The mixture was concentrated under reduced pressure, diluted with CH2Cl2 and 
washed with aqueous HCl (1.0 M). The aqueous solution was further extracted with CH2Cl2. The combined organic layers 
were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. Purifications by flash col-
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umn chromatography or recrystallisation yielded the trans N-chloroformylimidazolidinone 2. NOTE: Highly toxic phos-
gene solutions must be handled inside the fumehood. Needles and used glassware should be quenched with 1 M aqueous 
HCl inside the fumehood. 
General Procedure 2: Alkylation of N-chloroformylimidazolidinones 
A solution of N-chloroformylimidazolidinone (1.0 mmol) in THF (10.0 mL) was degassed by bubbling with N2 for 15 min 
and cooled to -78 °C. KHMDS (1.1 mL, 1.1 mmol, 1.1 equiv., 1.0 M in THF) was added dropwise. After stirring for 5 min, the 
alkyl halide (1.1 mmol, 1.1 equiv.) was added dropwise. After stirring for 2 h at -78 °C, the reaction was quenched with wa-
ter (10.0 mL). The mixture was extracted with EtOAc (2 x 10.0 mL). The combined organic layers were washed with brine 
(2 x 10.0 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography to yield the alkylated product 3. 
General Procedure 3: Hydrolysis of alkylated N-chloroformylimidazolidinones  
The N-chloroformylimidazolidinone 3 (1.0 equiv.) was dissolved in a mixture of trifluoroacetic acid and 6.0 M HCl (1:4 
ratio. 0.05 M) in a microwave vial. 1 g of Dowex 50WX8 (prewashed sequentially with methanol and deionised water) was 
added to the reaction mixture. The sealed vial was heated in a microwave reactor at 130 °C (10-12 bar) for 4 h (reaction 
progress was monitored by TLC analysis). The reaction mixture was concentrated under reduced pressure. The Dowex 
resin (with adsorbed crude product) was washed with 20 mL of methanol, 50 mL of deionised water (to remove the me-
thylamine hydrochloride byproduct), and finally 50 mL of 3% aqueous ammonia solution to elute the desired product. 
Concentration of the ammoniacal fractions under reduced pressure afforded the product. 
General Procedure 4: CBz protection 
In flask A, a solution of trans N-chloroformylimidazolidinone (1.0 mmol, 1.0 equiv.) in THF (0.2M) was degassed by bub-
bling with N2 for 15 min and cooled to 0 °C. In flask B, NaH (60% suspension in mineral oil, 1.05 equiv.) was added to a 
solution of benzyl alcohol (1.1 equiv.) in dry THF (2 mL) at 0 °C. The solution was stirred for 30 minutes at 0 °C. The con-
tent of flask A was added to flask B dropwise over 10 min at 0 °C. The reaction mixture was warmed to RT and allowed to 
stir for 1 h. The reaction was quenched with water (10.0 mL). The mixture was extracted with EtOAc (2 x 10.0 mL). The 
combined organic layers were washed with brine (2 x 10.0 mL), dried over MgSO4, filtered and concentrated under re-
duced pressure. The crude product was purified by flash column chromatography to yield the desired product. 
(2S,5S)-5-Benzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2a) 
Following general procedure 1, the corresponding imine (24.83 g, 107.24 mmol) was dissolved in dry THF (220 mL) and 
treated with phosgene solution (133.10 mL, 160.87 mmol), followed by pyridine (13.24 mL, 163.845 mmol). After acidic 
work-up, the crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, 
pet.ether/EtOAc, 6:1) to yield the title compound (29.10 g, 90%) as a white solid. Data in agreement with our previously 
reported values.15  
(2S,5S)-5-(4-(Benzyloxy)benzyl)-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2b) 
Following general procedure 1, the corresponding imine (28.78 g, 82.02 mmol) was dissolved in dry THF (163 mL) and 
treated with phosgene solution (94.97 mL, 122.61 mmol), followed by pyridine (14.39 mL, 162.61 mmol). After acidic work-
up, the crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 6:1) 
to afford the title compound (26.70 g, 81%) as a white solid. Data in agreement with our previously reported values.15 
(2S,5S)-2-(tert-Butyl)-5-(3,4-dimethoxybenzyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2c) 
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Following general procedure 1, the corresponding imine (21.56 g, 70.40 mmol) was dissolved in dry THF (140 mL) and 
treated with phosgene solution (80.59 mL, 105.55 mmol), followed by pyridine (5.8 mL, 140.80 mmol). After acidic work-
up, the crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 1:2) 
to afford the title compound (18.43 g, 85%) as a beige solid. Data in agreement with our previously reported values.16 
(2S,5S)-2-(tert-Butyl)-5-(3-fluorobenzyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2d) 
Following general procedure 1, the corresponding imine (13.30 g, 50.33 mmol) was dissolved in dry THF (98 mL) and 
treated with phosgene solution (58.94 mL, 75.2677 mmol), followed by pyridine (7.60 mL, 100.51 mmol). The crude prod-
uct (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 6:1) to afford the title 
compound (1.70 g, 82%) as a white solid. Data in agreement with our previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3-methyl-5-(4-nitrobenzyl)-4-oxoimidazolidine-1-carbonyl chloride (2e) 
Following general procedure 1, the corresponding imine (2.60 g, 9.36 mmol) was dissolved in dry THF (17.70 mL) and 
treated with phosgene solution (10.77 mL, 14.04 mmol), followed by pyridine (0.74 mL, 18.57 mmol). After acidic work-up, 
the crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 6:1) to 
afford the title compound (2.5 g, 77%) as a white solid. Data in agreement with previously reported values.16  
(2S,5S)-2-(tert-Butyl)-3-methyl-5-(naphthalen-1-ylmethyl)-4-oxoimidazolidine-1-carbonyl chloride (2f) 
Following general procedure 1, the corresponding imine (5.80 g, 20.73 mmol) was dissolved in dry THF (41 mL) and treat-
ed with phosgene solution (43.50 mL, 31.11 mmol), followed by pyridine (0.70 mL, 8.58 mmol). After acidic work-up, the 
crude product (97:3 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 2:1) to yield 
the title compound (5.50 g, 74%) as a beige solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3-methyl-5-(naphthalen-2-ylmethyl)-4-oxoimidazolidine-1-carbonyl chloride (2g) 
Following general procedure 1, the corresponding imine (2.28 g, 7.70 mmol) was dissolved in dry THF (15 mL) and treated 
with phosgene solution (9 mL, 11.58 mmol), followed by pyridine (1.25 mL, 15 mmol). After acidic work-up, the crude 
product (96:4 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 2:1) to yield the 
title compound (2.00 g, 73%) as a yellow solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-phenethylimidazolidine-1-carbonyl chloride (2h) 
Following general procedure 1, the corresponding imine (2.90 g, 11.14 mmol) was dissolved in dry THF (23 mL) and treated 
with phosgene solution (9.00 mL, 16.80 mmol), followed by pyridine (1.86 mL, 22.3 mmol). After acidic work-up, the 
crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 6:1) to yield 
the title compound (2.90 g, 83%) as a colourless solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-5-(furan-2-ylmethyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2i) 
Following general procedure 1, the corresponding imine (0.84 g, 3.57 mmol, 1.0 eq.) was dissolved in dry THF (7.00 mL) 
and treated with phosgene solution (4.032 mL, 5.352 mmol), followed by pyridine (0.59 mL, 7.15 mmol). After acidic work-
up, the crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 6:1) 
to afford the title compound (0.83 g, 83%) as a beige solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-(thiophen-2-ylmethyl)imidazolidine-1-carbonyl chloride (2j) 
Following general procedure 1, the corresponding imine (2.10 g, 8.53 mmol) was dissolved in dry THF (16 mL) and treated 
with phosgene solution (9.60 mL, 12.60 mmol), followed by pyridine (1.34 mL, 16.71 mmol). After acidic work-up, the 
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crude product  (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 6:1) to 
afford the title compound (1.90 g, 73%) as a colourless solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-(thiophen-3-ylmethyl)imidazolidine-1-carbonyl chloride (2k) 
Following general procedure 1, the corresponding imine (0.58 g, 2.3 mmol) was dissolved in dry THF (4.6 mL, 0.5 M) and 
treated with phosgene solution (2.64 mL, 3.45 mmol), followed by pyridine (0.37 mL, 4.60 mmol). After acidic work-up, 
the crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 6:1) to 
afford the title compound (0.56 g, 78%) as a white solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-((1-tosyl-1H-indol-3-yl)methyl)imidazolidine-1-carbonyl chloride (2l) 
Following general procedure 1, the corresponding imine (2.46 g, 5.60 mmol) was then dissolved in dry THF (11.2 mL) and 
treated with phosgene solution (6.5 mL, 8.39 mmol), followed by pyridine (0.91 mL, 11.19 mmol). After acidic work-up, the 
crude product (96:4 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2; pet. ether/EtOAc 90:10 → 
pet. ether/EtOAc 20:80) to afford the title compound (2.44 g, 82%) as a white solid. Data in agreement with previously 
reported values.18 
(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-phenylimidazolidine-1-carbonyl chloride (2m) 
Following general procedure 1, the corresponding imine (9.12 g, 41.60 mmol) was dissolved in dry THF (80 mL) and treat-
ed with phosgene solution (42 mL, 63.40 mmol), followed by pyridine (7.2 mL, 84.80 mmol). After acidic work-up, the 
crude product (>99:1 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 2:1) to yield 
the title compound (3.54 g, 72%) as a colourless solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3,5-dimethyl-4-oxoimidazolidine-1-carbonyl chloride (2n) 
Following general procedure 1, the corresponding imine (30.00 g, 176.25 mmol) was dissolved in dry THF (352 mL) and 
treated with phosgene solution (200 mL, 39.00 mmol), followed by pyridine (28 mL, 352.50 mmol). After acidic work-up, 
the crude product (98:2 trans:cis diastereomeric ratio by 1H NMR) was purified by recrystallisation from Et2O/n-Hexane 
(1:1) to afford the title compound (35.2 g, 88%) as a white crystalline solid. Data in agreement with previously reported 
values.16 
(2S,5S)-2-(tert-Butyl)-5-isobutyl-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2o)  
Following general procedure 1, the corresponding imine (4.30 g, 20.24 mmol) was dissolved in dry THF (40.3 mL) and 
treated with phosgene solution (23.35 mL, 30.35 mmol), followed by pyridine (3.27 mL, 40.47 mmol). After acidic work-up, 
the crude product (> 95:5 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2; pet. ether/EtOAc 93:7 
→ pet. ether/EtOAc 40:60) to afford the title compound (4.18 g, 74%) as a white crystalline solid. Data in agreement with 
previously reported values.15 
(2S,5S)-2-(tert-Butyl)-5-isopropyl-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2p) 
Following general procedure 1, the corresponding imine (1.20 g, 6.05 mmol) was dissolved in dry THF (12.10 mL) and 
treated with phosgene solution (6.98 mL, 9.08 mmol), followed by pyridine (0.98 mL, 12.10 mmol). The crude product was 
recrystallized using PE/Et2O/CH2Cl2 to give the title compound (1.07 g, 68%) as an off-white crystalline solid. Data in 
agreement with previously reported values.15 
(2S,5S)-5-Allyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (2q) 
Following general procedure 1, the corresponding imine (2.85 g, 14.52 mmol) was dissolved in dry THF (29 mL) and treat-
ed with phosgene solution (16.80 mL, 21.78 mmol), followed by pyridine (2.3 mL, 29 mmol, 2.0 eq.). After acidic work-up, 
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the crude (>95:5 trans:cis diastereomeric ratio by 1H NMR) was chromatographed (SiO2, pet.ether/EtOAc, 4:1) to afford 
the title compound (3.42 g, 90%) as a pale yellow solid. Data in agreement with previously reported values.16 
(2S,5S)-2-(tert-Butyl)-3-methyl-5-(2-(methylthio)ethyl)-4-oxoimidazolidine-1-carbonyl chloride (2r)  
Following general procedure 1, the corresponding imine (570 mg, 2.47 mmol) was then dissolved in dry THF (4.95 mL) 
and treated with phosgene solution (2.85 mL, 3.71 mmol), followed by pyridine (0.40 mL, 4.95 mmol). After acidic work-
up, the trans N-chloroformylimidazolidinone (697 mg, 95%, >95:5 trans:cis diastereomeric ratio by 1H NMR) was obtained 
as an orange oil and used without further purification. Data in agreement with previously reported values.18 
(2S,5R)-5-Allyl-5-benzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (3a) 
Following general procedure 2, N-chloroformylimidazolidinone 2a (200 mg, 0.65 mmol), KHMDS (0.77 mL, 0.77 mmol, 1.2 
equiv., 1.0 M in THF) and allyl bromide (0.17 mL, 1.95 mmol, 3 equiv.) gave, after purification by automated FC (SiO2, 
pet.ether/EtOAc, 6:1), the title compound (180 mg, 86%) as a white solid. mp: 80-82 °C, Rf = 0.45 (pet.ether/EtOAc = 6:1); [𝛂]𝐃𝟐𝟓 = -104 (c = 1 in CHCl3); IR νmax = 2974 (C-H), 1737(C=O), 1712 (C=O); 1H NMR (500 MHz, CDCl3) (mixture of rotamers 
in a 0.52:0.48 ratio) δ 7.37 – 7.33 (m, 1H), 7.30 – 7.08 (m, 4H), 5.55 – 5.47 (m, 0.48H), 5.47 – 5.31 (m, 0.52H), 5.27 – 5.22 (m, 
0.96H), 5.20 – 5.12 (m, 1.04H), 5.02 (s, 0.48H), 4.95 (s, 0.52H), 3.55 (d, J = 14.2 Hz, 0.96H), 3.35 (d, J = 14.2 Hz, 1.04H), 3.27 
(dt, J = 14.4, 7.7 Hz, 0.52H), 3.10 (dd, J = 14.4, 7.7 Hz, 0.52H), 2.97 (s, 1.44H), 2.94 (d, J = 1.1 Hz, 1.56H), 2.67 (dd, J = 14.4, 7.7 
Hz, 0.48H), 2.45 (dd, J = 14.0, 5.9 Hz, 0.48H), 0.81 (s, 4.32H), 0.56 (s, 4.68H). 13C {1H} NMR (125 MHz, CDCl3) δ 170.5, 170.4, 
150.1, 147.8, 135.7, 135.6, 131.3, 131.2, 130.5, 130.1, 128.6, 128.5, 127.5, 127.4, 121.9, 121.7, 83.3, 83.2, 73.8, 71.9, 43.0, 42.0, 41.3, 39.3, 
38.4, 38.3, 31.4, 31.3, 27.4, 26.5. HRMS C19H25ClN2O2 [M + H]+ calculated: 349.1677, found: 349.1671. 
(2R,5R)-5-Benzyl-2-(tert-butyl)-5-(4-chlorobenzyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (3b) 
Following general procedure 2, N-chloroformylimidazolidinone cis-2b15 (200 mg, 0.65 mmol, 1.0 equiv.), KHMDS (0.77 
mL, 0.77 mmol, 1.2 equiv., 1.0 M in THF) and 4-chlorobenzyl bromide (146 mg, 0.71 mmol, 1.1 equiv.) gave, after purifica-
tion by automated FC (SiO2, pet.ether/EtOAc, 4:1), the title compound (200 mg, 73%) as a colourless solid. mp: 127-129 °C, 
1H NMR (500 MHz, CDCl3) (mixture of rotamers in a 0.55:0.45 ratio) δ 7.43 – 7.39 (m, 1H), 7.36 – 7.32 (m, 1H), 7.30 – 7.27 
(m, 2H), 7.26 – 7.21 (m, 3H), 7.14 – 7.06 (m, 2H), 4.34 (s, 0.55H), 4.15 (s, 0.45H), 3.75 (dd, J = 19.3, 14.2 Hz, 1H), 3.60 (d, J = 
14.0 Hz, 1H), 3.53 – 3.44 (m, 2H), 3.16 (d, J = 14.2 Hz, 0.55H), 3.00 (d, J = 14.0 Hz, 0.55H), 2.70 (s, 1.65H), 2.62 (s, 1.35H), 0.68 
(s, 4.95H), 0.39 (s, 4.05H). 13C {1H} NMR (125 MHz, CDCl3) δ 169.8, 169.6, 149.3, 148.2, 135.6, 135.6, 133.9, 133.5, 133.1, 132.8, 
131.9, 131.7, 131.4, 131.4, 128.8, 128.7, 128.6, 128.5, 127.7, 127.6, 82.8, 82.7, 75.3, 73.7, 43.2, 42.1, 41.4, 39.8, 38.5, 38.4, 31.3, 31.3, 
27.4, 26.5. HRMS C23H26Cl2N2O2 [M + H]+ calculated: 433.1444, found: 433.1464. 
(2S,5R)-5-Benzyl-2-(tert-butyl)-3-methyl-5-(2-methylallyl)-4-oxoimidazolidine-1-carbonyl chloride (3c) 
Following general procedure 2, N-chloroformylimidazolidinone 2a (150 mg, 0.49 mmol), KHMDS (1M in THF, 0.53 mL, 
0.53 mmol), and 3-bromo-2-methylprop-1-ene (73 µL, 0.73 mmol) gave, after purification by FCC (SiO2; pet. ether/EtOAc 
90:10 → pet. ether/EtOAc 80:20), the title compound (119 mg, 67%) as a white solid. mp: 87-89 °C, Rf 0.32 (SiO2; pet. 
ether/EtOAc 80:20); [𝛂]𝐃𝟐𝟒 = -120° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2968 (C–H), 1738 (C=O), 1712 (C=O); 1H NMR (400 
MHz, CDCl3) (mixture of rotamers in a 0.53:0.47 ratio) δ 7.45 – 7.12 (m, 5H), 5.10 – 4.70 (m, 3H), 3.55 (d, J = 14.0 Hz, 
0.53H), 3.41 – 3.24 (m, 2H), 3.16 (d, J = 14.2 Hz, 0.47H), 2.97 (s, 1.41H), 2.92 (s, 1.59H), 2.62 (d, J = 14.4 Hz, 0.53H), 2.41 (d, J = 
14.2 Hz, 0.47H), 1.61 (m, 3H), 0.85 (s, 4.3H), 0.58 (s, 4.7H); 13C {1H} NMR (101 MHz, CDCl3) δ 170.5, 170.4, 149.8, 147.7, 139.3, 
139.0, 135.7, 135.6, 131.5, 131.4, 128.6, 128.4, 127.6, 127.4, 118.4, 117.8, 83.1, 73.0, 71.3, 45.5, 42.9, 42.4, 42.2, 38.6, 31.7, 31.6, 27.6, 
26.8, 23.2; HRMS C20H28ClN2O2 [M+H]+ calculated: 363.1834, found 363.1826. 
(2S,5S)-2-(tert-Butyl)-5-ethyl-3,5-dimethyl-4-oxoimidazolidine-1-carbonyl chloride (3d) 
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Following general procedure 2, N-chloroformylimidazolidinone 2n (150 mg, 0.65 mmol, 1.0 equiv.), KHMDS (0.77 mL, 0.77 
mmol, 1.2 equiv., 1.0 M in THF) and ethyl iodide (0.26 mL, 3.25 mmol, 5 equiv.) gave, after purification by automated FC 
(SiO2, pet.ether/EtOAc, 4:1), the title compound (141 mg, 85%) as a colourless oil. Rf = 0.36 (pet.ether/EtOAc = 4:1); [𝛂]𝐃𝟐𝟓 = 
–116 (c = 1 in CHCl3); IR νmax = 2974 (C-H), 1737 (C=O), 1712 (C=O); 1H NMR (500 MHz, CDCl3) δ 5.18 (s, 0.51H), 5.16 (s, 
0.49H), 3.02 (s, 1.47H), 3.01 (s, 1.53H), 2.49 (dq, J = 14.7, 7.4 Hz, 0.51H), 2.35 (dq, J = 14.7, 7.4 Hz, 0.49H), 1.94 (dq, J = 14.8, 
7.4 Hz, 0.51H), 1.77 (dq, J = 14.6, 7.3 Hz, 0.49H), 1.63 (s, 1.53H), 1.56 (s, 1.47H), 1.08 (s, 4.59H), 1.00 (s, 4.41H), 0.63 (t, J = 7.4 
Hz, 1.53H), 0.59 (t, J = 7.3 Hz, 1.47H). 13C {1H} NMR (125 MHz, CDCl3) δ 172.4, 172.2, 149.2, 145.7, 83.3, 82.9, 69.7, 67.7, 39.6, 
39.2, 32.0, 31.7, 31.4, 28.9, 27.6, 26.9, 23.4, 22.7, 8.0. HRMS C12H22ClN2O2 [M + H]+ calculated: 261.1364, found: 261.1372. The 
relative stereochemistry was assigned by NOE experiments (See Supporting Information). 
(2S,5S)-2-(tert-Butyl)-3,5-dimethyl-4-oxo-5-(prop-2-yn-1-yl)imidazolidine-1-carbonyl chloride (3e) 
Following general procedure 2, N-chloroformylimidazolidinone 2n (100 mg, 0.43 mmol), KHMDS (1M in THF, 0.47 mL, 
0.47 mmol) and propargyl bromide (80% in toluene, 53 µL, 0.47 mmol) gave, after purification by automated FC (SiO2; 
pet. ether/Et2O 85:15 → pet. ether/Et2O 0:100), the title compound (72 mg, 62%) as a colourless oil. Rf 0.33 (SiO2; pet. 
ether/Et2O 50:50); [𝛂]𝐃𝟐𝟒 = –40 (c = 0.5 in CHCl3); IR (neat, cm-1): νmax 2968 (C–H), 1738 (C=O), 1716 (C=O); 1H NMR (400 
MHz, CDCl3) (mixture of rotamers in a 0.50:0.50 ratio) δ 5.23 (s, 0.5H), 5.21 (s, 0.5H), 3.38 (dd, J = 17.3, 2.7 Hz, 0.5H), 3.28 
(dd, J = 16.9, 2.6 Hz, 0.5H), 3.07 (m, 3H), 2.87 (dd, J = 17.3, 2.7 Hz, 0.5H), 2.68 (dd, J = 16.9, 2.6 Hz, 0.5H), 2.03 (t, J = 2.6 Hz, 
0.5H), 2.00 (t, J = 2.6 Hz, 0.5H), 1.65 (s, 1.5H), 1.58 (s, 1.5H), 1.10 (s, 4.5H), 1.02 (s, 4.5H); 13C {1H} NMR (101 MHz, CDCl3) δ 
171.7, 171.4, 148.6, 147.4, 84.0, 83.7, 78.2, 77.6, 72.8, 71.8, 68.6, 66.4, 39.5, 39.1, 32.2, 31.9, 30.2, 27.6, 27.3, 26.9, 22.6, 21.8; 
HRMS C13H19ClN2O2Na [M+Na]+ calculated: 293.1027, found 293.1036. 
(2S,5S)-2-(tert-Butyl)-5-(4-chlorobenzyl)-3,5-dimethyl-4-oxoimidazolidine-1-carbonyl chloride (3f) 
Following general procedure 2, N-chloroformylimidazolidinone 2n (150 mg, 0.65 mmol), KHMDS (1M in THF, 0.77 mL, 
0.77 mmol), and 4-chlorobenzyl bromide (146 mg, 0.72 mmol) gave, after purification by flash column chromatography, 
the title compound (170 mg, 74%) as a colourless foam. Rf = 0.23 (pet.ether/EtOAc 6:1).	[𝛂]𝐃𝟐𝟓 = -28 (c = 1 in CHCl3); IR νmax 
= 2983 (C-H), 1736 (C=O), 1709 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.22 (dd, J = 8.6, 2.3 Hz, 2H), 7.08 (t, J = 8.5 Hz, 2H), 
4.59 (s, 0.57H), 4.52 (s, 0.43H), 3.72 (d, J = 14.2 Hz, 0.43H), 3.59 (d, J = 14.0 Hz, 0.57H), 3.11 (d, J = 14.2 Hz, 0.43H), 3.02 (d, J 
= 14.0 Hz, 0.57H), 2.78 (s, 1.71H), 2.72 (s, 1.29H), 1.81 (s, 1.29H), 1.73 (s, 1.71H), 1.02 (s, 5.13H), 0.92 (s, 3.87H). 13C {1H} NMR 
(125 MHz, CDCl3) δ 171.5, 171.5, 148.3, 146.9, 133.7, 133.5, 133.4, 133.3, 131.6, 131.3, 128.6, 128.4, 82.8, 82.7, 70.5, 68.3, 42.8, 40.2, 
39.9, 39.4, 31.8, 31.5, 27.7, 26.9, 23.7, 22.7. HRMS C17H23Cl2N2O2 [M + H]+ calculated: 357.11311, found: 357.114325. 
(2S,5R)-5-Allyl-2-(tert-butyl)-3-methyl-4-oxo-5-phenylimidazolidine-1-carbonyl chloride (3g) 
Following general procedure 2, N-chloroformylimidazolidinone 2m, KHMDS (0.61 mL, 0.61 mmol, 1.2 equiv., 1.0 M in 
THF) and allyl bromide (0.13 mL, 1.53 mmol, 3 equiv.) gave, after purification by automated FC (SiO2, pet.ether/EtOAc, 
6:1), the title compound (140 mg, 82%) as a colourless solid. mp: 113-115 °C, [𝛂]𝐃𝟐𝟓 = +124 (c = 1 in CHCl3); IR νmax = 2974 (C-
H), 1737 (C=O), 1712 (C=O); 1H NMR (500 MHz, CDCl3) (mixture of rotamers in a 0.90:0.10 ratio) δ 7.74 – 7.62 (m, 2H), 7.33 
– 7.22 (m, 2H), 7.21 – 7.16 (m, 1H), 5.49 – 5.45 (m, 0.1H), 5.44 – 5.35 (m, 0.9H), 5.28 – 5.25 (m, 0.1H), 5.23 (s, 0.9H), 5.20 – 
5.09 (m, 2H), 3.40 (dd, J = 14.5, 8.7 Hz, 0.1H), 3.31 (dd, J = 14.4, 8.8 Hz, 0.9H), 3.25 (ddt, J = 14.6, 5.9, 1.5 Hz, 0.1H), 3.00 (s, 
2.7H), 2.96 (s, 0.3H), 2.82 (ddt, J = 14.4, 5.7, 1.5 Hz, 0.9H), 0.88 (s, 0.9H), 0.79 (s, 8.1H). 13C {1H} NMR (125 MHz, CDCl3) δ 
170.2, 169.7, 150.8, 148.2, 139.4, 137.4, 131.1, 130.3, 128.5, 128.2, 128.1, 128.0, 128.0, 126.7, 126.1, 126.1, 122.1, 121.8, 84.2, 83.2, 74.6, 
72.1, 44.8, 42.8, 39.3, 38.7, 31.9, 31.8, 27.2, 26.9. HRMS C18H24ClN2O2 [M + H]+ calculated: 335.152082, found: 335.152680. The 
relative stereochemistry was assigned by NOE experiments (See NOE section in Supporting Information). 
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(S)-2-Amino-2-methylbutanoic acid [L-Isovaline] (4) 
Following general procedure 3, alkylated N-chloroformylimidazolidinone 3d (50 mg, 0.19 mmol) was suspended in a mix-
ture of TFA – 6.0 M HCl (1:4 ratio) (3.8 mL, 0.05 M) with Dowex 50WX8 (1 g) and heated in a microwave reactor at 130 °C 
(10 bar) for 4 h to afford the title compound (19 mg, 87%) as a white foam. [𝛂]𝐃𝟐𝟔 = +12 (c = 1 in H2O); 1H NMR (500 MHz, 
CD3OD) δ 1.93 (dq, J = 15.1, 7.6 Hz, 1H), 1.70 (dq, J = 14.7, 7.5 Hz, 1H), 1.44 (s, 3H), 0.98 (t, J = 7.5 Hz, 3H). 13C {1H} NMR (125 
MHz, CD3OD) δ 175.1, 61.5, 30.5, 21.9, 7.2. Data in agreement with reported values in literature.19 
(R)-2-Amino-2-benzyl-3-(4-chlorophenyl)-N-methylpropanamide(5) 
Following general procedure 3, alkylated N-chloroformylimidazolidinone 3b (50 mg, 0.11 mmol) was suspended in a mix-
ture of TFA – 6.0 M HCl (1:4 ratio) (2.3 mL, 0.05 M) with Dowex 50WX8 (1 g) and heated in a microwave reactor at 130 °C 
(10 bar) for 4 h to afford the title compound (25 mg, 75%) as a white foam. [𝛂]𝐃𝟐𝟔 = -8 (c = 1 in MeOH); IR νmax = 3325 (NH2 
amide), 3291 (NH amide), 3315 (NH2 amine), 2924 (C-H), 1689 (C=O amide); 1H NMR (500 MHz, CD3OD) δ 7.36 – 7.29 (m, 
5H), 7.24 – 7.17 (m, 4H), 3.45 – 3.34 (m, 2H), 2.97 (dd, J = 28.0, 14.2 Hz, 1H), 2.70 (dd, J = 13.1, 1.7 Hz, 1H), 2.53 (s, 3H). 13C 
{1H} NMR (101 MHz, CD3OD) δ 177.7, 137.7, 136.7, 135.7, 134.6, 133.8, 133.1, 132.8, 131.6, 131.3, 129.8, 129.7, 129.3, 129.2, 128.6, 
127.9, 63.9, 47.2, 46.4, 43.6, 42.8, 26.2. HRMS C17H19ClN2O [M + H]+ calculated: 303.1259, found: 303.1256. 
Benzyl (2S,5S)-5-benzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carboxylate (6) 
Following general procedure 4, benzyl alcohol (0.14 ml, 0.71 mmol) in dry THF (1 mL), NaH (60% suspension in mineral 
oil, 39 mg, 0.71 mmol) and N-chloroformylimidazolidinone 2a (200 mg, 0.65 mmol) in THF (3 mL) gave, after purification 
by automated FC (SiO2; pet. ether/EtOAc 8:1 → pet. ether/ EtOAc, 3:1), the title compound (150 mg, 63%) as a colourless 
solid. Rf 0.06 (SiO2; pet. ether/ EtOAc, 3:1); [𝛂]𝐃𝟐𝟓 = +12 (c = 1 in CHCl3); IR (neat, cm-1): νmax 2968 (C–H), 1738 (C=O), 1716 
(C=O); 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.30 (m, 3H), 7.25 – 7.15 (m, 7H), 5.07 (d, J = 11.7 Hz, 1H), 5.00 (s, 1H), 4.75 (s, 
1H), 4.37 (t, J = 6.5 Hz, 1H), 3.23 (dd, J = 13.7, 6.5 Hz, 1H), 3.07 – 2.93 (m, 4H), 1.05 (s, 9H). 13C {1H} NMR (125 MHz, CDCl3) δ 
171.2, 156.8, 138.1, 135.7, 130.2, 129.6, 128.6, 128.5, 128.4, 128.4, 128.4, 126.6, 82.7, 67.9, 62.0, 39.9, 37.6, 31.5, 26.8. HRMS 
C23H29N2O3 [M + H]+ calculated: 381.2115, found: 381.2121. The relative stereochemistry was assigned by NOE experiments 
(See NOE section in Supporting Information). The structure and relative stereochemistry were also confirmed by X-ray 
crystallography after recrystallisation from dichloromethane and pentane. 
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